Reduction in cardiovascular related hospitalization with nocturnal home hemodialysis

Clinical Nephrology

Volumn 69, Issue 1, 2008, Pages 33-39

  Bergman, A ^a   Fenton, S S A ^a   Richardson, R M A ^a   Chan, Christopher T ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b NONE   (Canada)

Author keywords

Anemia; Calcium phosphate balance; Cardiovascular disease; Hospitalization; Nocturnal home hemodialysis

Indexed keywords

ALBUMIN; BICARBONATE; CALCIUM; CREATININE; FERRITIN; HEMOGLOBIN; PARATHYROID HORMONE; PHOSPHATE; POTASSIUM;

ADULT; ANEMIA; ARTICLE; BIOCHEMISTRY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COHORT ANALYSIS; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EMERGENCY HEALTH SERVICE; FEMALE; HOME DIALYSIS; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NOCTURNAL HOME DIALYSIS; PHOSPHATE BLOOD LEVEL; RISK REDUCTION; TREATMENT OUTCOME; UREMIA; VASCULAR ACCESS;

EID: 38349008292     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP69033     Document Type: Article

References (33)

1. Block GA, Hulbert-Shearon TE et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998; 31: 607-617.
2. Chan C, Floras JS et al. Improvement in ejection fraction by nocturnal haemodialysis in end-stage renal failure patients with coexisting heart failure. Nephrol Dial Transplant. 2002a; 17: 1518-1521.
3. Chan CT, Floras JS et al. Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis. Kidney Int. 2002b; 61: 2235-2239.
4. Chan CT, Harvey PJ et al. Short-term blood pressure, noradrenergic, and vascular effects of nocturnal home hemodialysis. Hypertension. 2003; 42: 925-931.
5. Chan CT, Hanly P et al. Impact of nocturnal hemodialysis on the variability of heart rate and duration of hypoxemia during sleep. Kidney Int. 2004; 65: 661-665.
6. Chan CT, Jain V et al. Nocturnal hemodialysis increases arterial baroreflex sensitivity and compliance and normalizes blood pressure of hypertensive patients with end-stage renal disease. Kidney Int. 2005; 68: 338-344.
7. Chan CT, Li SH et al. Nocturnal hemodialysis is associated with restoration of impaired endothelial progenitor cell biology in end-stage renal disease. Am J Physiol Renal Physiol. 2005; 289: F679-684.
8. Collins AJ. Influence of target hemoglobin in dialysis patients on morbidity and mortality. Kidney Int. 2002; 80 (Suppl): 44-48.
9. Collins AJ. Cardiovascular mortality in end-stage renal disease. Am J Med Sci. 2003; 325: 163-167.
10. Daugirdas JT, Greene T et al. Relationship between apparent (single-pool) and true (double-pool) urea distribution volume. Kidney Int. 1999; 56: 1928-1933.
11. Foley RN. Clinical epidemiology of cardiac disease in dialysis patients: left ventricular hypertrophy, ischemic heart disease, and cardiac failure. Semin Dial. 2003; 16: 111-117.
12. Foley RN, Parfrey PS et al. The impact of anemia on cardiomyopathy, morbidity, and and mortality in end-stage renal disease. Am J Kidney Dis. 1996; 28: 53-61.
13. Ganesh SK, Stack AG et al. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001; 12: 2131-2138.
14. Hanly PJ, Pierratos A. Improvement of sleep apnea in patients with chronic renal failure who undergo nocturnal hemodialysis. New Engl J Med. 2001; 344: 102-107.
15. Hemmelgarn B R, Manns BJ et al. Adapting the Charlson Comorbidity Index for use in patients with ESRD. Am J Kidney Dis. 2003; 42: 125-132.
16. Ifudu O, Feldman J et al. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. N Engl J Med. 1996; 334: 420-425.
17. Jindal KK, Manuel A et al. Percent reduction in blood urea concentration during hemodialysis (PRU). A simple and accurate method to estimate Kt/V urea. ASAIO Transactions. 1987; 33: 286-288.
18. Kundhal K, Pierratos A et al. Newer paradigms in renal replacement therapy: will they alter cardiovascular outcomes? Cardiol Clin. 2005; 23(3): 385-391.
19. Lacombe C. Resistance to erythropoietin. N Engl J Med. 1996; 334(10): 660-662.
20. Levin A, Djurdjev O et al. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis. 2005; 46: 799-811.
21. Locatelli F, Del Vecchio L. Dialysis adequacy and response to erythropoietic agents: what is the evidence base? Nephrol Dial Transplant. 2003; 18 (Suppl 8): viii29-35.
22. London GM, Marchais SJ et al. Cardiovascular risk in end-stage renal disease: vascular aspects. Nephrol Dial Transplant. 2000; 15 (Suppl 5): 97-104.
23. Ma JZ, Ebben J et al. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol. 1999; 10: 610-619.
24. Mucsi I, Hercz G et al. Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int. 1998; 53: 1399-1404.
25. Muirhead N, Laupacis A et al. Erythropoietin for anaemia in haemodialysis patients: results of a maintenance study (the Canadian Erythropoietin Study Group). Nephrol Dial Transplant. 1992; 7: 811-816.
26. Perl J, Lok CE et al. Central venous catheter outcomes in nocturnal hemodialysis. Kidney Int. 2006; 70: 1348-1354.
27. Pierratos A, McFarlane P et al. Quotidian dialysis - update 2005. Curt Opin Nephrol Hypertens. 2005; 14: 119-124.
28. Schwartz DI, Pierratos A et al. Impact of nocturnal home hemodialysis on anemia management in patients with end-stage renal disease. Clin Nephrol. 2005; 63: 202-208.
29. Szmitko PE, Fedak PW et al. Endothelial progenitor cells: new hope for a broken heart. Circulation. 2003; 107: 3093-3100.
30. Tonelli M, Sacks F et al. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation. 2005; 112: 2627-2633.
31. Volkova N, Arab L. Evidence-based systematic literature review of hemoglobin/hematocrit and all-cause mortality in dialysis patients. Am J Kidney Dis. 2006; 47: 24-36.
32. Yuen D, Richardson R M et al. Quotidian nocturnal hemodialysis improves cytokine profile and enhances erythropoietin responsiveness. Asaio J. 2005; 51: 236-241.
33. Yuen D, Pierratos A et al. The natural history of coronary calcification progression in a cohort of nocturnal haemodialysis patients. Nephrol Dial Transplant. 2006; 21: 1407-1412.